The team behind a first-of-its-kind skin cancer test have received a £2.45m investment boost as they look to launch the test on the NHS and in the USA this summer.
The female-led AMLo Biosciences is a spin-out firm which started at Newcastle University and has developed a brand new test which can determine whether a skin cancer patient's melanoma is low-risk - which would mean it could be treated in a less intensive way. This would see fewer patients have to undergo treatment they may not need and also free up NHS capacity to treat those who do require more care.
Melanoma is one of the cancers that dogged Sir Bobby Robson - and currently around 16,000 people a year in the UK are diagnosed with it. But for most, if caught early, the cancer can be removed - though in around 10% of cases, stage one melanomas can spready or return.
